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Abstract
Background Inflammatory bowel disease (IBD) [including
Crohn’s disease (CD) and ulcerative colitis (UC)] consti-
tutes an important clinical problem. The pathogenesis of
IBD remains unclear. It is believed that immune dysfunc-
tion, inflammatory mediators and oxidative damage play
crucial roles in development of IBD. The condition is
clinically associated with symptoms ranging from mild to
severe during relapses, depending on the affected segment
of the gastrointestinal tract. Bloody diarrhea with mucus,
abdominal pain, weight loss and anemia are initial symp-
toms of both CD and UC. Differences between diseases
become more evident in time, along with the development
of intestinal and extraintestinal complications. Mangiferin
(1,3,6,7-tetrahydroxyxanthone-C-2-b-D-glucoside), a natu-
ral polyphenol in plants, exerts antioxidant and anti-
inflammatory effects making it an interesting option for the
treatment of inflammatory pathologies associated with
oxidative stress in humans, such as IBD.
Purpose The aim of the current study was to elucidate the
impact of mangiferin on colon tissues in 2,4,6-trini-
trobenzensulfonic acid (TNBS)-induced colitis in rats.
Methods Mangiferin was obtained from Belamcanda chi-
nensis rhizomes by a multistage process. Groups of rats
were pre-treated with 10, 30 or 100 mg/kg of mangiferin,
or with distilled water administered intragastrically for
16 days. An ethanol solution of TNBS or saline was given
rectally on the day 15 of the experiment. The experiment
was terminated on the day 17. The colon was removed,
cleaned, weighed and examined macro- and microscopi-
cally. Determination of tumor necrosis factor a (TNF-a),
interleukin 17 (IL-17), malondialdehyde (MDA) levels and
superoxide dismutase (SOD) activity were performed
spectrophotometrically in homogenates of colon tissues.
Results Rats in the TNBS group developed symptoms of
colitis, including: body weight loss, colon mass index
increase and damage of intestinal tissues with concomitant
increase in TNF-a, IL-17, MDA levels and decreased SOD
activity. In non-TNBS-treated rats mangiferin did not cause
any changes of studied parameters. Pre-treatment with
mangiferin exerted a protective effect, reducing the inten-
sity of damage caused by TNBS. Mangiferin at the doses of
30 and 100 mg/kg reduced the macro- and microscopic
damage score and the MDA level in colon tissues. Only at
the dose of 100 mg/kg, mangiferin decreased TNF-a and
IL-17 concentrations, and SOD activity in colon tissues.
Conclusion Mangiferin attenuates inflammatory changes
of colon tissues in experimental, TNBS-induced colitis in
rats. Protective effect exerted by mangiferin depends pri-
marily on its anti-inflammatory activity and secondarily on
its antioxidant properties.
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Inflammatory bowel disease (IBD) is an important and
commonly encountered clinical problem. The incidence of
IBD has considerably increased in recent years in both
Western and Eastern societies, also in children. Almost
25% of new diagnoses of the disease are made in patients
under 18 years of age. The most common forms of IBD are
Crohn’s disease (CD) and ulcerative colitis (UC). IBD is
characterized by a chronic, relapsing inflammatory condi-
tion of the gastrointestinal tract, with both overlapping and
distinct pathological and clinical features. Symptoms range
from mild to severe during relapses and may disappear
during remissions, depending on the involved segment of
the gastrointestinal tract. Initially, both CD and UC are
characterized by low-grade fever, fatigue, bloody diarrhea
accompanied by mucorrhea, abdominal pain with cramps,
unintended weight loss with reduced appetite and anemia.
Differences between Crohn’s disease and ulcerative colitis
patients become more evident with progression of the
disease, along with development of intestinal and extrain-
testinal complications (Sartor 2006; Vasovic et al. 2016).
The pathogenesis of IBD is multifactorial and remains
not completely understood. It is presumed that a complex
interaction between genetic, environmental or microbial
factors may lead to enhanced immune response, involving
increased migration, proliferation and activation of Th1,
Th2 and Th17 cells and increased concentrations of pro-
inflammatory cytokines, including tumor necrosis factor a
(TNF-a) and interleukin 17 (IL-17), that determine the
development and persistence of inflammation. Moreover,
oxidative stress and a loss of mucosal epithelial barrier may
contribute to the development of intestinal inflammation
(Pavlick et al. 2002; Sartor 2006; Shen and Durum 2010).
Despite a significant progress in IBD therapy, clinicians
still expect more effective and safer medicines. Presently,
aminosalicylates are considered drugs of choice for the
management of majority of cases, while glucocorticos-
teroids, immunosuppressants and biological agents are
reserved for more severe forms of the disease (van Assche
et al. 2010; Dignass et al. 2012). The pharmacological
treatment is fraught with severe side effects of drugs. Those
effects are particularly important in the context of chronic
and relapsing nature of IBD and the necessity of long-term
pharmacotherapy (Kenneth and McQuaid 2012). Thus,
there is a need for identification of new, more efficient and
safer therapies for IBD. The assessment of substances
obtained from plants, traditionally used in various inflam-
matory conditions, is one of the approaches for
development of future IBD treatments.
Mangiferin (2-C-b-D-glucopyranosyl-1,3,6,7-tetrahy-
droxyxanthone) belongs to xanthonoids, a class of natural
components referred to as polyphenols. Mangiferin is
mainly isolated from leaves, bark and fruit peel of Man-
gifera indica (L.) and rhizomes of Belamcanda chinensis
(L.) DC. (syn.: Iris domestica (L.) Goldbl. & Mabb.;
English: blackberry lilly, leopard flower; Traditional Chi-
nese Medicine: she gan). These rhizomes are used in East
Asian phytotherapy systems as an antipyretic, antiphlo-
gistic, analgesic and expectorant agent. Studies with
mangiferin based on experimental in vitro and in vivo
assays have demonstrated its antioxidant, anti-inflamma-
tory, immunomodulatory, antimicrobial, analgesic and
radioprotective effects (Matkowski et al. 2013; Wauthoz
et al. 2007).
This study was designed to elucidate the impact of
mangiferin on 2,4,6-trinitrobenzensulfonic (TNBS) acid-
induced colitis in rats.
Materials and methods
Plant material
Mangiferin was isolated from Belamcanda chinensis rhi-
zomes obtained from the Botanical Garden of the Faculty
of Pharmacy, Wroclaw Medical University, Wroclaw,
Poland. A voucher specimen was deposited in the
Department of Pharmaceutical Biology and Botany of the
Faculty of Pharmacy, Wroclaw Medical University, Wro-
claw, Poland (Voucher No. 24.2014). First, rhizomes were
dried and powdered. Crude material was defatted with
hexane and extracted with methanol for 24 h. The metha-
nol extract was evaporated, suspended in 20% methanol
and partitioned with diethyl ether followed by butanol. The
butanol extract was subjected to solid-phase extraction on
C-18 silica cartridges eluted with water and subsequently
with 40% methanol. The 40% methanol fraction was fur-
ther separated with reversed-phase flash chromatography
using C-18 silica as the stationary phase eluted with 1%
acetic acid and 25% acetonitrile under 0.3 Bar pressure of
nitrogen. Mangiferin was eluted as the first fraction. Pure
mangiferin was obtained after recrystallization from etha-
nol and drying under nitrogen. Liquid chromatography-
mass spectrometry (Fig. 1) and quantitative analysis were
carried out, respectively, to confirm the chemical identity
and purity of obtained mangiferin.
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Animals
Male Wistar rats (160–220 g) were purchased from the
Department of Pathomorphology of the Wroclaw Medical
University (Wroclaw, Poland). All rats were housed, two
per cage, in polypropylene cages with water ad libitum.
The rats were kept in controlled environment (temperature
of 21–24 C and 55–60% humidity) with a 12 h light/dark
cycle with free access to standard rodent chow (Agropol,
Poland) except for the single procedure of deprivation. The
study was approved by the First Local Ethics Committee
for Experiments on Animals in Wroclaw (No. 18/2013).
Chemicals
Chemicals used in the experiment were as follows: trini-
trobenzensulfonic acid (Sigma Aldrich, Germany);
pentobarbital sodium (Biowet, Poland); physiological sal-
ine (Polpharma S.A., Poland); ethanol and formaldehyde
(Avantor, Poland); acetic acid, methanol, butanol, diethyl
































Fig. 1 Multiple reaction monitoring (MRM) chromatograms recorded during the analysis of the methanol extract of mangiferin standard (a) and
obtained mangiferin (b). In the whole range of peak there is only one mass 421.1 m/z
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ether, hexane (Chempur, Poland); acetonitrile (Merck,
Germany) and C-18 silica gel (Sigma Aldrich, Germany).
Design of the experiment
After 2 weeks of adaptation, 79 rats were randomly divided
into eight groups (9–10 rats in each) as follows: one group
receiving distilled water intragastrically (i.g.) and once
saline rectally (control group, K); three groups of rats
receiving mangiferin at doses of 10, 30 or 100 mg/kg i.g.
and once saline rectally (M10, M30, M100, respectively), one
group receiving distilled water i.g. and once TNBS solution
rectally (colitis group, C), and three groups receiving
mangiferin at doses of 10, 30 or 100 mg/kg i.g. and a single
rectal administration of TNBS solution (CM10, CM30,
CM100, respectively). Because of very limited data con-
cerning pure mangiferin doses in rat experimental models
(mainly in other then IBD conditions) we have decided to
use the dose-dependent model of the experiment with three
doses of mangiferin. Distilled water or aqueous solution of
mangiferin was given once daily by gastric tube (4 ml/kg
b.w.) for 16 consecutive days. 0.3 ml of TNBS ethanol
solution or saline was given rectally on day 15 of the
experiment, after 24-h of food deprivation. Animals were
observed and weighted every day. Forty-eight hours after
induction of colitis rats were killed by cervical dislocation
under deep pentobarbital anesthesia (53.4 mg/kg). The
distal 8 cm segment of the colon was collected from each
animal, placed on ice-cold plate and longitudinally opened,
cleaned, weighed and macroscopically examined. After-
wards samples were divided into two pieces. One piece was
fixed in 4% buffered formaldehyde for histopathological
examination. The histological sections were from paraffin
embedded tissues and they were stained using three
methods: hematoxylin-eosin, Giemsa and alcian blue. The
second piece was homogenized in phosphate-buffered
saline solution (pH 7.4) and centrifuged at 40,000 rpm for
10 min at 4 C. Obtained supernatants were transferred
into new tubes and stored at -80 C for biochemical
analyses.
Induction of colitis
Colonic inflammation was induced according to the pro-
cedure originally described by Morris et al. (1989). Briefly,
rats were anesthetized with intramuscular injection of
ketamine (75 mg/kg) and medetomidine (0.5 mg/kg) and
were positioned on their right side. Then TNBS (50 mg/kg)
dissolved in 50% ethanol (v/v) was instilled into the colon
using a flexible polyethylene catheter (external diameter
2 mm) and inserted 8 cm deep into the rectum. Following
the instillation of TNBS, animals were kept in
Trendelenburg position for 5 min to prevent leakage of the
instilled solution.
Assessment of body weight and colon mass index
The difference of body weight between days 15 and 17 of
the experiment was determined. The colon mass index (the
ratio of excised 8 cm of colon weight to total body weight)
was calculated.
Assessment of macro- and microscopic damage
of the colon
The severity of colon tissue damage was measured using
macro- and microscopic examination. The colon was
examined visually immediately after resection. The severity
of macroscopically visible changes in the mucous membrane
was scored using the 0–5 scale according to the criteria
described by Ga´lvez et al. (2001). Colonic specimens
demonstrating macroscopic injury of the greater extent col-
lected from each rat exposed to TNBS, or equivalent colonic
specimens from non-colitic rats, were selected for the his-
tological assessment. Selected specimens were fixed in 4%
buffered formaldehyde and embedded in paraffin. There-
after, tissues samples were cut into 4 lm-thick slices using a
rotary microtome (Sakura Accu-cut SRM, Netherlands) and
placed on glass slides. Preparations were stained using three
methods: hematoxylin-eosin, Giemsa and alcian blue for
histological assessment of colonic damage, cell infiltration
and mucus content, respectively. Histological damage was
evaluated using the scoring scale described in the legend to
Fig. 2, based on the criteria previously presented by Arribas
et al. (2010). The final result was the sum of points (0–25)
scored by evaluation of each criterion. All slides were coded
to prevent observer bias during the assessment. For charac-
terization of histopathological changes all tissue sections
were examined by two independent pathologist using the
Olympus BX51 microscope, based on photographs taken
from colon samples made with the Olympus DP72 digital
camera. The assessment was carried out based on the image
analysis system Olympus Soft Imaging Solutions GmbH—
cell^D ver. 3.2. (Olympus, Germany).
The assessment of TNF-a and IL-17 levels in colon
tissues
TNF-a and IL-17 concentrations were assayed in obtained
supernatants with quantitative enzyme immunoassay rat
specific kits: Rat TNF-a Elisa Kit and Rat IL-17 Elisa Kit,
respectively, (Diaclone, Francja) according to the manu-
facturer’s instructions. Concentrations of TNF-a and IL-17
were expressed as pg/ml.
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Determination of the MDA level and SOD activity
in colon tissues
Both parameters were assessed spectrophotometrically
(Marcel S350 Pro spectrophotometer, Poland) in obtained
supernatants using assay kits according to their manufac-
turers’ instructions. Malondialdehyde (MDA)
concentration was assayed using the Bioxytech-MDA-586
Kit (OxisResearch, USA) and its level was expressed as
lmol/ml. Superoxide dismutase (SOD) activity was ana-
lyzed using the Ransod Kit (Randox Laboratories, UK).
Values of SOD activity were expressed as U/mg protein.
Total protein concentration in homogenates was assayed in
commercial, certified laboratory using the enzymatic
method.
Statistical analysis
All data are presented as mean values ± standard deviation
(SD). Statistical differences between studied parameters
were analyzed using one-way analysis of variance
(ANOVA) and multiple comparisons with the Tukey’s post
hoc test. The relationship between studied parameters was
evaluated by the Pearson correlation coefficient. All sta-
tistical analyses were performed with GraphPad Prism
version 5.0 (GraphPad Software, USA), with statistical
significance set at p\ 0.05.
Results
Detailed effects (including the level of significance) of
mangiferin on body weight, colon mass index, macro- and
microscopic damages, TNF-a and IL-17 and MDA levels
and SOD activity in colon tissues are presented in the
Fig. 2. Summing up briefly, TNBS caused significant loss
of body weight, increased colon mass index, elicited
macro- and microscopic damages in colon tissues,
increased TNF-a, IL-17 and MDA concentrations and
decreased SOD activity, in comparison to the control
group. Administration of mangiferin at the highest dose
(100 mg/kg) significantly protected from TNBS-induced
changes, such as macro- and microscopic damage, TNF-a,
IL-17, MDA concentration increase and increased SOD
activity, but not from TNBS-induced body weight loss and
increased colon mass index. Mangiferin administered at the
medium dose (30 mg/kg) protected only from macro- and
microscopic damage and MDA level increase. The lowest
dose of mangiferin (10 mg/kg) did not reverse any of the
TNBS-induced changes. Administration of mangiferin in
rats non-treated with TNBS did not exert any changes in
any of studied parameters in comparison to the control
group. Macroscopic changes of TNBS-induced colitis
involved bowel wall thickening, hyperemia and edema.
Microscopic examination of colon samples showed an
intense interruption of colon tissues with ulceration and
inflammation involving not only the epithelial layer but
also all intestinal layers in some of studied specimens. The
ulceration was associated with transmural infiltration of
lymphocytes, macrophages and neutrophils. The mucosal
infiltration of inflammatory cells was considerably high
and it was minor in the submucosa and muscular layer.
Rats with TNBS-induced colitis also showed structural
distortion of crypts, desquamated areas or loss of epithe-
lium. The inflammatory process was also linked with
goblet cell depletion leading to the decline of the mucus
layer of the epithelium (Fig. 3, 4). In comparison with the
TNBS group mangiferin pre-treatment (30 or 100 mg/kg)
before the induction of colitis significantly attenuated the
colonic lesions and resulted in reduced score of macro- and
microscopic damage. A histological examination of colonic
samples from rats pre-treated with mangiferin (30 or
100 mg/kg) demonstrated a pronounced recovery of tissues
of the colon, with decreased extent and reduced intensity of
ulceration (Fig. 3), decreased transmural infiltration of
inflammatory cells (Fig. 4a), increased amount of goblet
cells refilled with their mucin constituents and restored
epithelial cell layer (Fig. 4b). Mangiferin at the lowest dose
(10 mg/kg) had no protective effect against TNBS-induced
changes. The action of mangiferin on TNBS-induced
colonic damage was dose dependent. It was significantly
cFig. 2 The impact of mangiferin on rat: body weight (a), colon mass
index (b), macroscopic damage of colon tissues (c), microscopic
damage of colon tissues (d), colon tissues TNF-a concentration (e),
colon tissues IL-17 concentration (f), colon tissues MDA concentra-
tion (g), SOD activity in colon tissues (h) in experimental groups;
K—the control group, M10, M30, M100—groups receiving, respec-
tively, 10, 30 or 100 mg/kg of mangiferin intragastrically, C—the
group receiving only TNBS rectally, CM10, CM30, CM100—groups
receiving 10, 30 or 100 mg/kg of mangiferin with TNBS, respec-
tively. Macroscopic evaluation of colonic tissue damage according to
the criteria described by Galvez et al.: score 0 (no damage); score 1
(hyperemia, no ulcers); score 2 (linear ulcer with no significant
inflammation); score 3 (linear ulcer with inflammation at one site);
score 4 (two or more sites of ulceration or inflammation and
ulceration or inflammation extending\1 cm); score 5 (two or more
major sites of ulceration or inflammation extending[1 cm along the
length of the colon) Microscopic evaluation of colonic tissue damage:
in mucosal epithelium and lamina propria: ulceration (0–4), mononu-
clear cell infiltration (0–3), polymorphonuclear cell infiltration (0–3);
in submucosa: edema (0–3), mononuclear cell infiltration (0–3),
polymorphonuclear cell infiltration (0–3); in muscular layer: mononu-
clear cell infiltration (0–3), polymorphonuclear cell infiltration (0–3).
Scoring scale: 0—none, 1—mild, 2—moderate, 3—severe, 4—full-
thickness; maximum score: 25. Results are presented as mean
values ± SD. Differences ***p\ 0.001 vs the control group;
**p\ 0.01 vs the control group; *p\ 0.05 vs the control group;
###p\ 0.001 vs the TNBS group; ##p\ 0.01 vs the TNBS group;
#p\ 0.05 vs the TNBS group were deemed statistically significant
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higher at the dose of 100 mg/kg compared to 30 mg/kg.
Administration of mangiferin to rats non-exposed to TNBS
did not exert any pathological changes of all studied
parameters. Correlation coefficients between the micro-
scopically evaluated degree damage of colonic tissue and
TNF-a, IL-17, MDA concentrations (r = 0.692; 0.561;
0.663, respectively) and the SOD activity (r = -0.804)
were statistically significant at p\ 0.001. There was no
directly proportional correlation between the score of
microscopic damage and the above-mentioned parameters,
but it has been demonstrated that the degree of microscopic
damage done to the colon decreased along with decreasing
TNF-a, IL-17 and MDA concentrations and increasing
SOD activity.
Discussion
Experimental animal models of IBD are valuable tools
widely used in preclinical studies. In our study the TNBS
model of IBD had been chosen because it is well charac-
terized and shares some biochemical and immunological
features and symptoms with the disease in humans
(Westbrook et al. 2010).
Some efforts have been recently made to identify and
extract purely natural compounds, particularly plant-
derived ones, that could restore the normal immune
response altered in IBD and act as protective agents in
various inflammatory disorders. Polyphenols, represented
by mangiferin, are one of the most important groups of
Fig. 3 Microscopic appearance
of colon tissues after
hematoxylin-eosin staining
showed that mangiferin reduces
histological damage; control
group (K), groups receiving
mangiferin at the doses of 10 or
30 or 100 mg/kg (M10, M30,
M100, respectively), group
receiving only TNBS (C),
groups receiving mangiferin at
the doses of 10 or 30 or 100 mg/
kg with TNBS (CM10, CM30,
CM100, respectively);
magnification 2009
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natural substances, demonstrating strong anti-inflammatory
and antioxidative properties (Ma´rquez et al. 2010). Man-
giferin has been widely evaluated in various in vitro assays
that suggested its protective effect against oxidative dam-
age and development of inflammation in tissues
(Matkowski et al. 2013; Wauthoz et al. 2007). Our study
Fig. 4 Microscopic appearance
of colon tissues after Giemsa
staining showed that mangiferin
reduces the inflammatory cells
infiltration (a); and after Alcian
blue staining showed that
mangiferin prevents loss of
mucus layer (b); control group
(K), group receiving only TNBS
(C), groups receiving
mangiferin at the doses of 10 or
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was aimed at determination of the impact of mangiferin
extracted from Belamcanda chinensis rhizome on the
model of experimental colitis induced by rectal TNBS
administration.
Based on results of the present study mangiferin did not
exert any toxic effect on colon tissues. In the group of rats
receiving mangiferin, but non-exposed to TNBS (M10,
M30 and M100), no significant changes of all studied
parameters were observed in comparison to the control
group (group K). Rats exposed to TNBS (group C)
developed colitis leading to body weight loss, colon mass
index increase as well as macro- and microscopic damage
in intestinal tissues compared to the control group. The
inflamed colon of rats with TNBS-induced colitis demon-
strated mucosal hyperemia, edema, increased mural
thickness and distortion of crypts. Additionally, TNBS-
induced colitis involved epithelial layer damage, depletion
of goblet cells with insufficient production of mucus and a
transmural infiltration of inflammatory cells. The mecha-
nism of TNBS-induced intestinal inflammation is likely
associated with accumulation of inflammatory cells in the
mucosa and impairment of the epithelial monolayer on the
mucosal intestinal surface, reflected by an excessive pro-
duction of pro-inflammatory cytokines and induction of
oxidative damage. In the present study, the inflammatory
changes in colon tissues caused by TNBS administration
were associated with increased TNF-a, IL-17, MDA
expression and decreased SOD activity compared to the
control group.
Based on the macroscopic, histological and biochemical
results obtained for mangiferin pretreated groups with
subsequent experimental colitis (CM10, CM30 and
CM100), it can be concluded that mangiferin alleviates the
course of experimental IBD. Mangiferin at doses of 30 and
100 mg/kg, but not at the dose of 10 mg/kg, reduced the
intensity of experimental colitis in rats. Mangiferin at the
dose of 100 mg/kg reduced tissue damage caused by TNBS
to a greater extent than at the dose of 30 mg/kg, indicating
that the protective effect of mangiferin against colon tissue
injury is dose dependent. There was no statistically sig-
nificant difference in measured parameters between control
animals and those receiving mangiferin at the highest dose
(100 mg/kg) and TNBS. That suggests that mangiferin at
the highest dose not only reduces, but also prevents the
development of colitis. Additionally, a decrease of the
microscopic damage score accompanied by decreased
TNF-a, IL-17 and MDA concentrations and increased SOD
activity demonstrates the existence of a significant corre-
lation between the degree of severity of microscopic injury
and the anti-inflammatory and antioxidant action of man-
giferin. Our results demonstrated that all studied doses of
mangiferin exerted the antioxidant activity, but the anti-
inflammatory effect is evident only at the highest dose.
Tissue damage was the least pronounced when mangiferin
was used at the highest dose, indicating that the antioxidant
activity is insufficient to alleviate the course of experi-
mental inflammatory bowel disease and that the anti-
inflammatory activity of mangiferin plays a pivotal role in
the mechanism of protective action of the compound.
TNF-a and IL-17 play an important role both in the
pathogenesis of IBD and in experimental TNBS-induced
colitis. Both cytokines participate in the development of
intestinal inflammation ensuring regulation of proliferation,
maturation, migration of inflammatory cells and their
subsequent activation, enhancement of maturation of den-
dritic cells and increasing expression of matrix
metalloproteases, chemokines and other pro-inflammatory
cytokines (Shen and Durum 2010; Strober and Fuss 2011).
Thus, a decrease of infiltration and activation of lympho-
cytes and a subsequent decrease of production of pro-
inflammatory cytokines should contribute to reduction of
intensity of inflammatory response. That kind of action has
been demonstrated in this study and it is in line with targets
of modern biological pharmacotherapy. In this study a
trend was observed for lower secretion of TNF-a and IL-17
from intestinal tissue in animals pre-treated with mangi-
ferin before the TNBS administration, compared to animals
receiving only TNBS. TNF-a and IL-17 concentrations
were lower when mangiferin was used at the dose of
100 mg/kg. Mangiferin (30 and 100 mg/kg) decreased size
of ulcerated and inflamed areas, restored the epithelial
layer, augmented amount of goblet cells and acid glyco-
proteins (mainly sialomucins) and improved adherents and
tight junctions leading to appropriate cover of mucus layer
over the intestinal epithelium. Together, those results
demonstrate that mangiferin improves integrity of the
intestinal mucosal epithelial barrier. Restoration of the
intestinal barrier, separation of the gut lumen from the
immune system of lamina propria and reduced infiltration
of granulocytes, macrophages and lymphocytes into the
lamina propria indicate that mangiferin decreases the
excessive and uncontrolled antigenic stimulation of non-
specific and specific immune responses and inhibits
development of inflammation in the intestinal wall.
It is known that overproduction of reactive oxygen
species (ROS) in intestinal mucosal cells induces the
immune response leading to the injury of intestinal
epithelial cells, disruption of integrity of the intestinal
barrier and initiation of the intestinal inflammation. One of
the most important processes involving free radicals is lipid
peroxidation associated with oversynthesis of MDA (Pav-
lick et al. 2002). Our study demonstrated that mangiferin at
all studied doses decreased the MDA level in colon tissues
that was significantly increased after the administration of
TNBS. It suggests an important antioxidant activity of
mangiferin. One of several elements of the cell defense
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system is superoxide dismutase—the enzyme that catalyzes
the reaction of dismutation of the superoxide anion. In the
present paper only mangiferin administered at the highest
dose increased SOD activity in TNBS-induced inflamed
colon tissue, which suggests that the enzyme may be a less
sensitive predictor of oxidative stress compared to MDA.
The anti-inflammatory action of mangiferin demon-
strated in this paper is in line with results reported by other
authors. Ma´rquez et al. (2010) demonstrated a protective
effect of the Mangiferae indica extract (containing man-
giferin) on colonic tissues in experimental colitis caused by
dextran sulfate sodium. Tested extract decreased serum IL-
6 and TNF-a concentrations and reduced TNF-a and TNF-
a type 2 receptor expression in colonic tissues. Recently,
some studies using pure mangiferin have been also pub-
lished. However, all of them used the murine model of
colitis. Jeong et al. (2014) demonstrated that in TNBS-
induced intestinal inflammation in mice mangiferin
decreased the degree of colon shortening and reduced
macroscopic lesions. Furthermore, mangiferin diminished
expression of TNF-a, IL-1b, IL-6, inhibited IL-1R-asso-
ciated kinase phosphorylation and activation of the nuclear
factor kB. Similarly, the murine TNBS model of colitis was
used by Lim et al. (2016) who demonstrated that TNBS-
induced increase in TNF-a and IL-17 levels were reduced
by pre-treatment with mangiferin. Two more papers
reported the murine colitis model but the disease was
induced by a different irritating factor—dextran sodium
sulfate (DSS) in drinking water. Dou et al. (2014)
demonstrated mainly the anti-inflammatory action of
mangiferin (TNF-a, NF-jB, iNOS), whereas Somani et al.
(2016) focused mainly on oxidative stress parameters
(CAT, GSH, SOD, MDA, MPO), but also revealed some
anti-inflammatory effects of mangiferin.
To our best knowledge, our study is the first to
demonstrate the protective effect of pure mangiferin in
experimentally induced colitis in rats. Besides some basic
parameters of inflammation and oxidative stress that had
been also studied by other researchers, we broadened our
study by a more detailed histopathological evaluation.
Besides the standard hematoxylin-eosin staining, demon-
strating some typical micropathological damage to the
colon tissue, we used alcian blue and Giemsa staining. The
first reveals the colonic mucus layer with goblet cells
producing sialomucins, whereas Giemsa staining allows to
assess the magnitude of inflammatory cell infiltration to the
colonic tissue. Both these processes play a very important
role in the pathogenesis and determination of the degree of
damage in colitis. Based on these findings we may state
that mangiferin increases the integrity of epithelial layer
and significantly decreases colonic infiltration by inflam-
matory cells.
Restoration of integrity of the mucosal epithelial barrier,
decreased production of pro-inflammatory cytokines, pre-
vention of lipid peroxidation and increased activity of
antioxidant enzymes could be considered as mechanisms
involved in the beneficial effect exerted by mangiferin.
Considering findings from our and other studies it can be
assumed that mangiferin alleviates the course of experi-
mental colitis in rats and mice. Explanation of detailed
molecular mechanisms involved in the beneficial effect of
mangiferin requires further investigations of, e.g., the
impact of mangiferin on the expression of protective pro-
teins (e.g., trefoil factor 3, mucins), transcription factors,
caspases or mitogen-activated protein kinases engaged in
the activation of the inflammatory cascade in IBD.
Conclusions
In conclusion, mangiferin alleviates the colonic inflam-
matory changes in TNBS-induced experimental colitis in
rats. Pre-treatment with mangiferin at the doses of 30 and
100 mg/kg diminishes macro- and microscopic colonic
damage and leads to reduced MDA concentration. More-
over, pre-treatment with mangiferin at the dose of 100 mg/
kg decreases TNF-a and IL-17 concentrations and increa-
ses SOD activity. The antioxidant activity is evident after
administration of mangiferin at all studied doses and the
anti-inflammatory effect is observed only after adminis-
tration of mangiferin at the highest dose (100 mg/g). In
parallel, the least pronounced injury of colon tissue
develops following administration of mangiferin at the
highest dose. It may, therefore, be concluded that the
crucial mechanism underlying the protective impact of
mangiferin observed in this report is associated with the
compound’s anti-inflammatory action and that its antioxi-
dant action is of an accessory character.
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